222 related articles for article (PubMed ID: 36507548)
1. Effects of clozapine treatment on the improvement of substance use disorders other than nicotine in individuals with schizophrenia spectrum disorders: A systematic review and meta-analysis.
Rafizadeh R; Danilewitz M; Bousman CA; Mathew N; White RF; Bahji A; Honer WG; Schütz CG
J Psychopharmacol; 2023 Feb; 37(2):135-143. PubMed ID: 36507548
[TBL] [Abstract][Full Text] [Related]
2. Clozapine use in patients with schizophrenia and a comorbid substance use disorder: A systematic review.
Arranz B; Garriga M; García-Rizo C; San L
Eur Neuropsychopharmacol; 2018 Feb; 28(2):227-242. PubMed ID: 29273271
[TBL] [Abstract][Full Text] [Related]
3. Association of clozapine treatment and rate of methamphetamine or amphetamine relapses and abstinence among individuals with concurrent schizophrenia spectrum and amphetamine use disorder: A retrospective cohort study.
Rafizadeh R; Frankow L; Mahmood H; Poonia S; Mathew N; Danilewitz M; Bousman CA; Honer WG; Schütz CG
J Psychopharmacol; 2023 Oct; 37(10):1040-1048. PubMed ID: 37539972
[TBL] [Abstract][Full Text] [Related]
4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
5. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
6. Associations between antipsychotic use, substance use and relapse risk in patients with schizophrenia: real-world evidence from two national cohorts.
Lähteenvuo M; Luykx JJ; Taipale H; Mittendorfer-Rutz E; Tanskanen A; Batalla A; Tiihonen J
Br J Psychiatry; 2022 Dec; 221(6):758-765. PubMed ID: 36004532
[TBL] [Abstract][Full Text] [Related]
7. Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: a retrospective survey.
Zimmet SV; Strous RD; Burgess ES; Kohnstamm S; Green AI
J Clin Psychopharmacol; 2000 Feb; 20(1):94-8. PubMed ID: 10653215
[TBL] [Abstract][Full Text] [Related]
8. Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis.
Samara MT; Dold M; Gianatsi M; Nikolakopoulou A; Helfer B; Salanti G; Leucht S
JAMA Psychiatry; 2016 Mar; 73(3):199-210. PubMed ID: 26842482
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990-2017: Systematic review and meta-analysis.
Hunt GE; Large MM; Cleary M; Lai HMX; Saunders JB
Drug Alcohol Depend; 2018 Oct; 191():234-258. PubMed ID: 30153606
[TBL] [Abstract][Full Text] [Related]
10. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update.
Moore TA; Buchanan RW; Buckley PF; Chiles JA; Conley RR; Crismon ML; Essock SM; Finnerty M; Marder SR; Miller DD; McEvoy JP; Robinson DG; Schooler NR; Shon SP; Stroup TS; Miller AL
J Clin Psychiatry; 2007 Nov; 68(11):1751-62. PubMed ID: 18052569
[TBL] [Abstract][Full Text] [Related]
11. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.
Lewis SW; Davies L; Jones PB; Barnes TR; Murray RM; Kerwin R; Taylor D; Hayhurst KP; Markwick A; Lloyd H; Dunn G
Health Technol Assess; 2006 May; 10(17):iii-iv, ix-xi, 1-165. PubMed ID: 16707074
[TBL] [Abstract][Full Text] [Related]
12. Antipsychotic drug treatment of schizophrenic patients with substance abuse disorders.
San L; Arranz B; Martinez-Raga J
Eur Addict Res; 2007; 13(4):230-43. PubMed ID: 17851245
[TBL] [Abstract][Full Text] [Related]
13. Clozapine versus typical neuroleptic medication for schizophrenia.
Wahlbeck K; Cheine M; Essali MA
Cochrane Database Syst Rev; 2000; (2):CD000059. PubMed ID: 10796289
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials.
Chakos M; Lieberman J; Hoffman E; Bradford D; Sheitman B
Am J Psychiatry; 2001 Apr; 158(4):518-26. PubMed ID: 11282684
[TBL] [Abstract][Full Text] [Related]
15. Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone.
Green AI; Burgess ES; Dawson R; Zimmet SV; Strous RD
Schizophr Res; 2003 Mar; 60(1):81-5. PubMed ID: 12505141
[TBL] [Abstract][Full Text] [Related]
16. [Leponex, 10 years after -- a clinical review].
Llorca PM; Pere JJ
Encephale; 2004; 30(5):474-91. PubMed ID: 15627052
[TBL] [Abstract][Full Text] [Related]
17. Investigating Predictors of Clozapine Response in Adolescents with Schizophrenia and Schizoaffective Disorder.
Karacetin G; Ermis C; Bulanik Koc E; Saglam Y
J Child Adolesc Psychopharmacol; 2021 Sep; 31(7):504-510. PubMed ID: 34283936
[No Abstract] [Full Text] [Related]
18. The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia.
Drake RE; Xie H; McHugo GJ; Green AI
Schizophr Bull; 2000; 26(2):441-9. PubMed ID: 10885642
[TBL] [Abstract][Full Text] [Related]
19. Treatment pathway and patterns of clozapine prescribing for schizophrenia in New Zealand.
Wheeler AJ
Ann Pharmacother; 2008 Jun; 42(6):852-60. PubMed ID: 18477732
[TBL] [Abstract][Full Text] [Related]
20. Clozapine and paliperidone palmitate antipsychotic combination in treatment-resistant schizophrenia and other psychotic disorders: A retrospective 6-month mirror-image study.
Bioque M; Parellada E; García-Rizo C; Amoretti S; Fortea A; Oriolo G; Palau P; Boix-Quintana E; Safont G; Bernardo M
Eur Psychiatry; 2020 Jul; 63(1):e71. PubMed ID: 32669145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
